

# PROGRAM

## R&D Network - Antibody-drug conjugates

Time: February 4th 2015, kl 14.00 – 18.00

Venue: Auditorium, Stråleterapibyget, inngang J, OUS Radium Hospital, Ullernchausseen 70.



### PROGRAM

*Moderator: Arne Kolstad, MD, Dept. of Oncology, OUS Radiumhospitalet*

14:00–14:15 **Registration and coffee**

14:15–14:30 **Welcome and introduction**

- Arne Kolstad, MD, Dept. of Oncology, OUS Radiumhospitalet

14:30–15:00 **International key note speaker:**

**"Development of Antibody Drug Conjugates in hematologic malignancies"**

- Dr Rodney B. Smith MD, Senior International Medical Director, Roche

15:00–15:40 **International key note speaker:**

**"Antibody-drug conjugates and new treatment options"**

- Petter Veiby, PhD, global head of BioTherapeutics, Oncology DDU at Takeda Pharmaceuticals International, US.

**Q&A session**

**10 min coffee break**

- 16:00–16:30 **Clinical perspectives:**  
“Antibody-drug conjugates in treatment of lymphoma cancer patients”  
- Alexander Fosså, MD, Dept. of Oncology, OUS Radiumhospitalet
- 16:30–17:00 **The biotech perspective:**  
“Phase I study with new radioimmunoconjugate in indolent non-Hodgkin`s lymphomas. A Nordic Nanovector study”  
- Arne Kolstad, MD, Dept. of Oncology, OUS Radiumhospitalet
- 17:00–18:00 **Networking session with light refreshments**

**We look forward to an interesting evening!**

**Member companies Takeda Nycomed and Roche Norge AS kindly support the R&D Network**



Nycomed: a Takeda Company

**[SIGN UP HERE](#)**

**Any questions, please contact [mbi@oslocancercluster.no](mailto:mbi@oslocancercluster.no)**